EpiCast Report: Myelofibrosis - Epidemiology Forecast to 2025 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "EpiCast Report: Myelofibrosis - Epidemiology Forecast to 2025" drug pipelines to their offering.

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for myelofibrosis in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan).

It includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of myelofibrosis, PMF, PET MF and PPV MF based on county-specific studies published in peer-reviewed journals. The diagnosed incident cases of PMF are further segmented by sex, age (40-49 years, 50-59 years, 60-69 years, 70-79 years, and =80 years), mutations, and the international prognostic scoring system (IPSS) risk categorization.

The diagnosed prevalent cases of PMF are further segmented by sex and age (40-49 years, 50-59 years, 60-69 years, 70-79 years, and =80 years). GlobalData epidemiologists also provide sex-specific diagnosed incident and diagnosed prevalent cases of PET MF and PPV MF in the 7MM for the forecast period.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed incident cases of myelofibrosis (sum of the diagnosed incident cases of PMF and SMF) will increase from 3,791 cases in 2015 to 4,378 cases in 2025, at an Annual Growth Rate (AGR) of 1.55%. The US will have the highest number of diagnosed incident cases of myelofibrosis among the 7MM throughout the forecast period, while Japan will have the lowest.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of myelofibrosis will increase from 27,896 cases in 2015 to 32,030 cases in 2025, at an AGR of 1.48%. The US will have the highest number of diagnosed prevalent cases of myelofibrosis among the 7MM throughout the forecast period, while Japan will have the lowest.

Key Topics Covered:

1 Tables & Figures

2 Epidemiology

2.1 Risk Factors and Comorbidities

2.2 Global Trends

2.3 Forecast Methodology

2.4 Epidemiological Forecast of Myelofibrosis (2015-2025)

2.5 Discussion

3 Appendix

Companies Mentioned

- A&G Pharmaceutical Inc

- Abcodia Ltd

- Acobiom

- Andraka Technologies, LLC

- Applied Proteomics Inc

- Asuragen, Inc.

- Avant Diagnostics, Inc.

- BioMarker Strategies LLC

- Biouniver

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/c38328/epicast_report

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Leukemia Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Leukemia Drugs